Photonamic licenses PDT product to Bayer HealthCare's Intendis for skin treatment

SEPTEMBER 18, 2008 -- Intendis, a new company focused on treatment of skin disorders, has entered an agreement with Photonamic GmbH, developer of agents for fluorescence diagnosis (FD) and photodynamic therapy (PDT). Under the terms of the deal, Intendis -- which is part of Bayer HealthCare -- gains exclusive access outside the US to Photonamic's technology for use in PDT treatment of skin diseases -- and to develop, register and commercialize products based on it.

Sep 18th, 2008

SEPTEMBER 18, 2008 -- Intendis, a new company focused on the treatment of skin disorders has entered a licensing and development agreement with Photonamic GmbH, developer of agents for fluorescence diagnosis (FD) and photodynamic therapy (PDT).

Under the terms of the deal, Intendis -- which is part of Bayer HealthCare -- gains exclusive access outside the US to Photonamic's 5-aminolevulinic acid patch technology for use in the photodynamic therapy of skin diseases. And, Intendis now has the right to develop, register and commercialize products based on the technology under the brand names Alacare and Effala.

Dr Ulrich Kosciessa, managing director of Photonamic, said that the partnership is seen to offer "a very high level of success" in view of the experience Intendis brings as a global dermatology company. Photonamic is a subsidiary of medac GmbH

Bayer HealthCare recently announced it is acquiring the German firm Direvo Biotech AG, which specializes in protein engineering; that deal will likely be closed by the end of September.

More information:
Intendis
Photonamic

More in Biomedicine